Survodutide
As of the edition of 20 October 2026, Survodutide is a protein: in active development; acts on GCGR and GLP1R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Protein
- Registered trials
- 32, 0 stopped early
- Disease areas
- Nutrition and metabolism; Digestive system; Hormones; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 19 | 16 | 3 | 0 |
| Phase 2 | 4 | 3 | 1 | 0 |
| Phase 3 | 9 | 6 | 3 | 0 |
| All trials | 32 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Lead sponsor of trials | 2017 to now |